The role of sex hormones in psychopathology: Focus on schizophrenia

Primary Care - Clinics in Office Practice

Volumn 29, Issue 1, 2002, Pages 171-182

  Seeman, Mary V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEX HORMONE;

AKATHISIA; DISABILITY; DISEASE COURSE; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HORMONE ACTION; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE;

EID: 0036121078     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00080-0     Document Type: Review

References (67)

1. The female sex hormone oestrogen as a neuroprotectant
2. Role of estrogens in peripheral and cerebral glucose utilization
3. Emerging diversities in the mechanism of action of steroid hormones
4. Gender differences in patients with schizophrenia and substance abuse
5. Are adolescents the victims of raging hormones? Evidence for activational effects of hormones on moods and behavior at adolescence
6. CYP1A2 activity, gender and smoking as variables influencing the toxicity of caffeine
7. The incidence of operationally defined schizophrenia in Camberwell 1965-1985
8. Living with schizophrenia: The perspectives of women
9. Duration of pretreatment phases in schizophrenia: Women and men
10. Earlier puberty as a predictor of later onset of schizophrenia in women
11. Sex differences in neuroanatomical and clinical correlations in schizophrenia
12. Gender, premorbid characteristics and negative symptoms in schizophrenia
13. Estrogen control of central neurotransmission: Effect on mood, mental state, and memory
14. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia
15. Psychotropic drugs in pregnancy and lactation
16. Gender and the expression of schizophrenia
17. Gender and mortality in schizophrenia: Do women act like men?
18. Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators
19. Gender and schizophrenia outcome: A clinical trial of inpatient family intervention
20. Epidemiology of schizophrenia
21. Causes and consequences of the gender difference in age at onset of schizophrenia
22. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia
23. Variation in symptom severity over the menstrual cycle of schizophrenics
24. Neuroleptic intolerance
25. Predicting the long-term outcome of schizophrenia
26. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus
27. Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients
28. Gender as a risk factor for adverse events to medications
29. Selective estrogen receptor modulators
30. Differential olanzapine plasma concentrations by sex in a fixed-dose study
31. Sex differences in olfactory function in schizophrenia
32. A clinical trial of the effects of estrogen in acutely psychotic women
33. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics
34. The influence of gonadal steroids on the asymmetry of the cerebral cortex
35. Gender, estrogen, and schizophrenia
36. Psychotropic medications in lactation
37. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 cohort studies
38. Relationship of gender and menstrual status to symptoms and medication side-effects in patients with schizophrenia
39. Testosterone and dominance in men
40. Steroid Hormones: Effect on brain development and function
41. Estrogen actions in the central nervous system
42. Sexuality, reproduction, and family planning in women with schizophrenia
43. Gonadal steroid receptors: Possible roles in the etiology and therapy of cogntive and neurological disorders
44. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators
45. Social competence in schizophrenia: Premorbid adjustment, social skill, and domains of functioning
46. Mortality and causes of death in first admitted schizophrenic patients
47. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons
48. Long-term clinical outcome of schizophrenia with special reference to gender differences
49. Differences between male and female brains-Developmental mechanisms and implications
50. Lack of gender differences in neuroleptic response in patients with schizophrenia
51. Androgens, brain, and behavior
52. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis
53. Rapid membrane effects of steroid hormones: An emerging concept in neuroendocrinology
54. Gender and the onset of schizophrenia: Neurohumoral influences
55. Current outcome in schizophrenia: Women vs men
56. Neuroleptic prescription for men and women
57. Psychopathology in women and men: Focus on female hormones
58. Narratives of twenty to thirty years of schizophrenia outcome
59. A service for women with schizophrenia
60. Estrogen protects primary cortical neurons from glutamate toxicity
61. Female sex steroid hormones: From receptors to networks to performance actions on the sensorimotor system
62. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients
63. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics
64. Gender-related differences in pharmacokinetics and their clinical significance
65. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
66. 17b-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors
67. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: Correlation with dendritic spine density